Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Jun 5, 2017 Median Overall Survival in Expanded 20 mg Cohort Maintained at 12.5 Months and Continues to Compare Favorably to Historical Controls Impact of Steroids and Circulating Immune Cells Correlate with Immune Activation by IL-12 BOSTON, June 05, 201...
PDF
Jun 2, 2017 BOSTON, June 02, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference in New York on Friday, June 9, 2017 at 9:00 a.m. ET.To access a live audio webca...
PDF
May 17, 2017 BOSTON, May 17, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunot...
PDF
May 12, 2017 BOSTON, May 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it has priced an underwritten follow-on offering of 9,708,738 shares of its common stock at an offering price of $5.15 per share to a single institutional invest...
PDF
May 2, 2017 BOSTON, May 02, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immun...
PDF
May 1, 2017 — Advancing Plans to Initiate Pivotal Study for Ad-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer — - Company to Host Conference Call Today at 4:30 p.m. ET - BOSTON, ...
PDF
Apr 24, 2017 BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, May 1, 2017 at 4:30 p.m. ET to provide a corporate update and discuss financial results for...
PDF
Apr 20, 2017 BOSTON, April 20, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or ...
PDF
Apr 3, 2017 GERMANTOWN, Md. and BOSTON, April 03, 2017 (GLOBE NEWSWIRE) -- Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ZIOPHARM Oncology (NASDAQ:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Merck KGaA, Darm...
PDF
Mar 27, 2017 BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the receipt of positive guidance from an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for its lead gene therapy product candidate, Ad-RTS-hIL-...
PDF
Page:
1
... NextLast